article thumbnail

NHC Submits Comments on CMS Draft Guidance for IPAY 2028

Putting Patients First Blog

Inclusion of Part B Drugs: Scope, Challenges, and Opportunities The addition of provider-administered therapies covered under Medicare Part B to the IPAY 2028 cycle introduces a fundamentally different reimbursement and care delivery context than that of pharmacy-dispensed Part D drugs.

article thumbnail

Alfasigma sets stage for Jyseleca in axSpA after Phase III win

Pharmaceutical Technology

GlobalData predicts the axSpA market across the seven major pharmaceutical markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) will reach $3.6bn by 2028. Jyseleca in third development partnership The development of Jyseleca has seen several shifts in the pharmaceutical industry.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

N-FIS was developed to address a critical challenge in healthcare—needle phobia

Express Pharma

The technology is rapidly gaining traction among doctors in India, while internationally, institutions like Hungarys Heim Pl National Paediatric Institute, one of the largest paediatric hospitals has adopted N-FIS to enhance patient care. billion in 2028, growing at a compound annual growth rate (CAGR) of 14.16

article thumbnail

Merck agrees to acquire Verona Pharma for $10bn

Pharmaceutical Technology

Keytruda, which brought in $30bn in revenue in 2024, is approaching patent expirations set in 2028, and Merck is therefore intensifying efforts to restructure its portfolio, according to a report by Reuters. This agreement will enable the strong launch trajectory of this important medicine and provides value to Verona Pharma shareholders.”

article thumbnail

Revolution Medicines partners Royalty Pharma on $2bn funding

Pharmaceutical Technology

The first tranche will be received by Revolution, following US Food and Drug Administration (FDA) approval of daraxonrasib to treat metastatic PDAC by January 2028. The debt facility portion consists of three tranches totalling up to $750m linked directly to daraxonrasib’s commercial milestones. Sign up for our daily news round-up!

article thumbnail

ASCO 2025: Vepdegestrant Shows Superiority to Fulvestrant in ER+/HER2- Advanced Breast Cancer

Pharmacy Times

months versus 2.1 The findings were presented at the 2025 American Society of Clinical Oncology Annual Meeting, which was held in Chicago, Illinois.

article thumbnail

MSD shares drop 5% amid plans for $3bn cost cutting strategy

Pharmaceutical Technology

With biosimilars projected to enter the market by 2028, revenues from the branded drug are likely to face sharp declines – consistent with historical trends. Sales for the cancer drug grew 9% in Q2 on the back of further indication approvals – its $8bn in sales accounted for more than half of the company’s revenue.